Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Lipoprotein(a), or Lp(a), is a genetically driven cardiovascular risk factor affecting roughly 1 in 5 adults globally, yet population-wide testing remains below 1%. Updated AHA/ACC guidelines now make one-time Lp(a) screening a Class I recommendation for all adults. While no targeted therapies are approved yet, aggressively managing other risk factors can meaningfully reduce overall cardiovascular risk — and a wave of promising treatments is on the horizon.
Lp(a), or lipoprotein(a), is a highly atherogenic and prothrombotic lipid particle more strongly linked to cardiovascular morbidity and mortality than traditional markers like LDL cholesterol. Unlike LDL, Lp(a) levels are over 90% genetically determined — meaning diet and exercise won't budge them — and elevated levels affect roughly 1 in 5 adults, or more than 1 billion people worldwide. Despite this, population-level testing remains below 1%, a gap that updated AHA/ACC guidelines aim to close by making one-time Lp(a) screening a Class I recommendation for all adults.
With no approved targeted therapies yet, the current playbook focuses on aggressively managing every other modifiable cardiovascular risk factor — lowering LDL, controlling blood pressure, treating diabetes and obesity, and following the AHA's Life's Essential 8. PCSK9 inhibitors are recommended for high-risk patients who haven't hit LDL targets, though statins may slightly raise Lp(a) levels. Family screening is also critical, given approximately 47% concordance of elevated Lp(a) among first-degree relatives.
The therapeutic landscape is rapidly evolving. Pelacarsen (Ionis/Novartis), an antisense oligonucleotide that reduced Lp(a) by ~80% in Phase 2, recently failed its Phase 3 primary endpoint. Injectable siRNA therapies — olpasiran, lepodisiran, and zerlasiran — and oral agents like muvalaplin remain in active trials, with some showing up to 95% Lp(a) reduction. Gene-editing approaches targeting the LPA gene are also in early development.
Key Takeaways:
Why it matters: Lp(a) is not destiny, but identifying it early gives clinicians a critical window to intensify preventive care before a cardiovascular event occurs. As targeted therapies inch closer to approval, building screening habits now will position both patients and providers to act fast when options become available.
